MSNBC mentions Elixir Pharmaceuticals in an article on up and coming biotech companies. "Elixir Pharmaceuticals Inc. begins 2005 as an early-stage drug development company focused on the science of aging. But the company plans to end the year as a much more mature version of itself, with at least one drug generating revenue and two in clinical trials, thanks to some anticipated licensing deals with larger partners. And assuming those milestones are accomplished, Elixir plans to go even further and pursue an IPO." As you may recall, Elixir has been researching the biochemistry of calorie restriction and longevity genes. Financial success means more companies entering this field - a good thing for all of us in the long run.